RxDoctor Payments DataLook up a doctor →

Natalie Kerber

Family · Milwaukee, WINPI 1184075160

Payments from drug & device makers

$11,962in general payments, 2019–2025

Across 645 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Lilly USA, LLC$1K
  • Bayer$722
  • Pfizer$567
  • Ironwood Pharmaceuticals, Inc$512
  • plus $5K from 41 others

What the payments were for

  • Travel & lodging$30%
  • Food & beverage$11,85799%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,962 in reported general payments places this provider in the 95th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$23,502
Medicare patients
62
Services billed
456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$266,354
FarxigaDapagliflozin Propanediol117$143,958
LinzessLinaclotide102$119,408
TrulicityDulaglutide55$106,998
JardianceEmpagliflozin55$64,359
JanuviaSitagliptin Phosphate51$47,650
TradjentaLinagliptin56$47,080
EliquisApixaban27$29,357
Nurtec OdtRimegepant Sulfate14$25,888
Janumet XrSitagliptin Phos/Metformin Hcl15$21,992
SymbicortBudesonide/Formoterol Fumarate46$13,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$11,501
Humalog Kwikpen U-100Insulin Lispro31$9,391
Advair HfaFluticasone Propion/Salmeterol17$8,943
Albuterol Sulfate HfaAlbuterol Sulfate263$6,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$345$266,354166 claims
AstraZenecaFarxiga, Symbicort$2,046$157,053163 claims
AbbVieLinzess$2,013$119,408102 claims
Boehringer IngelheimJardiance, Tradjenta$263$111,439111 claims
Lilly USA, LLCTrulicity$1,114$106,99855 claims
MerckJanuvia, Janumet Xr$87$69,64266 claims
PfizerEliquis, Nurtec Odt$567$55,24541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,273 family providers in Wisconsin.

Other family in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →